Koji Product Supplementation' s Study (KPS)
sunnuntai 27. kesäkuuta 2021 päivittänyt: National Taiwan University Hospital
The Effect of Black Soybeans Koji Product Supplementation on Nutrients Absorption and Anti-aging Effect in Elderly
The present project is to identify the effect of black soy beans Koji product supplementation on nutrients absorption and anti-aging effect in elderly.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Previous studies show that supplementation of soy protein can effectively increase muscle mass and protein utilization.
Besides, soy extracts and isoflavones can stimulate muscle growth by activating the anabolic pathway of muscle tubules.
Black soybean is known to be rich in legume protein and isoflavones.We speculate that black soybean supplementation can improve the nutritional status and muscle mass of elderly people, thereby delaying the deterioration of muscular dystrophy in the elderly.
Reduce the occurrence of debilitation in the elderly.
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
60
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
-
Taipei City, Taiwan, 110
- Taipei Medical University
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Joo
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
1-2 items are necessary, 3-5 can match one item
- Age above 65 years
- Oral intake
- Walking speed: ≤ 0.8 m/s (measured by time for a 5-meter usual gait)
- Handgrip strength: Men: <26 kg Women: <18 kg (measured by electronic hand grip dynamometer)
- Calf circumference: Men: ≤ 34 cm Women: ≤ 33 cm
Exclusion Criteria:
- Participant in a moderate or strenuous exercise
- Unable to walk
- Unable to take in food from the mouth
- People who can't record or communicate.
- Refuse to accept the 3-day diet record
- Allergic to black soybeans or legumes
- Allergic to egg or milk
- Infected with disease and had to be hospitalized for treatment before 4 weeks of the intervention test start
- A patient who has been diagnosed with a malignant tumor or has a history of malignancy in the past year.
- The estimated glomerular filtration rate (eGFR) is less than 60 ml/min/1.73 m2 in the past three months.
- Hypothyroidism
- People who often have symptoms of gastrointestinal upset.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Black soybean koji product
Oral supplement 2 servings of black soybean koji product per day, for 10 weeks.
|
Black soybean koji product
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Body mass index
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure Participants' detected body composition by using bioelectrical impedance analysis (BIA) as a non-invasive test instrument to measure body mass index (BMI).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Fat mass
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test).
|
Measure Participants' detected body composition by using bioelectrical impedance analysis (BIA) as a non-invasive test instrument to measure fat mass.
|
Change from baseline outcome measure at 10th week (post-test).
|
|
Muscle mas
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure Participants' detected body composition by using bioelectrical impedance analysis (BIA) as a non-invasive test instrument to measure whole body and appendicular skeletal muscle mass.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Visceral fat area(VFA)
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure Participants' detected body composition by using bioelectrical impedance analysis (BIA) as a non-invasive test instrument to measure Visceral fat area(VFA) (cm2).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
BIA - Basal Metabolic Rate(BMR)
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure Participants' detected body composition by using bioelectrical impedance analysis (BIA) as a non-invasive test instrument to measure Basal Metabolic Rate(BMR) (kcal) . |
Change from baseline outcome measure at 10th week (post-test)
|
|
whole body Mineral
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure Participants' detected body composition by using bioelectrical impedance analysis (BIA) as a non-invasive test instrument to measure Mineral (kg) in whole body. . |
Change from baseline outcome measure at 10th week (post-test)
|
|
Bone Mineral Content
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure Participants' detected body composition by using bioelectrical impedance analysis (BIA) as a non-invasive test instrument to measure Bone Mineral Content (kg).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Cellular Water
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure Participants' detected body composition by using bioelectrical impedance analysis (BIA) as a non-invasive test instrument to measure whole body Extracellular Water (L), Intracellular Water(L), and Total Body Water (L), et al. . |
Change from baseline outcome measure at 10th week (post-test)
|
|
Muscle Strength - Hand Grip Strength
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Using hand grips to measure hand grip strength.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Physical Performance - Walking Speed
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measuring participants' speed to walk 5 ft.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Gut Microbiota Composition Analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Total genome DNA from samples was extracted from stool samples using the CTAB/SDS method.
One hundred ng of DNA was amplified with barcoded primers16S V3+V4: 314F-806R annealing to the V3-V4region of the 16S rRNA.
All of the PCR reactions were carried out using a Phusion® High-Fidelity PCR Master Mix (New England Biolabs, Location).
Samples with a bright main strip between 400 and 450bp were selected from 2% agarose gel for further experiments.
Mixture PCR products were purified using a Qiagen Gel Extraction Kit (Qiagen, Germany).
Libraries were generated with the TruSeq® DNA PCR-Free Sample Preparation Kit and quantified with Qubit and Q-PCR.
The purified DNA was then sequenced using the HiSeq2500 PE250 (Company, Location).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Gut Microbiota -derived Metabolite Analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measurements of short-chain fatty acids in feces during the experiment by using gas chromatography.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Inflammatory Cytokines TNF-α Analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
The inflammation-associated serum cytokines TNF-α was analyzed using colorimetric kits (Company, Location).
Thioredoxin (Cloud-Clone Corp, SEA702Hu, City, State, USA) and Complement Component 5a (Cloud-Clone Corp, SEA388Hu) in the urine was evaluated for the effects of inflammation states and also assessed using colorimetric kits.
The procedures followed the kit instructions and were measured using an ELISA reader (Bio Tek, PowerWave XS2, City, State, USA).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Inflammatory Cytokines IL-6 Analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
The inflammation-associated serum cytokines IL-6 was analyzed using colorimetric kits (Company, Location).
Thioredoxin (Cloud-Clone Corp, SEA702Hu, City, State, USA) and Complement Component 5a (Cloud-Clone Corp, SEA388Hu) in the urine was evaluated for the effects of inflammation states and also assessed using colorimetric kits.
The procedures followed the kit instructions and were measured using an ELISA reader (Bio Tek, PowerWave XS2, City, State, USA).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Inflammatory Cytokines IL-1β Analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
The inflammation-associated serum cytokines IL-1β (BioLegend, City, State, USA) was analyzed using colorimetric kits (Company, Location).
Thioredoxin (Cloud-Clone Corp, SEA702Hu, City, State, USA) and Complement Component 5a (Cloud-Clone Corp, SEA388Hu) in the urine was evaluated for the effects of inflammation states and also assessed using colorimetric kits.
The procedures followed the kit instructions and were measured using an ELISA reader (Bio Tek, PowerWave XS2, City, State, USA).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Red blood cells analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of red blood cells( M/ul)
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Hemoglobin analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of Hemoglobin(g/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
MCHC(g/dL) analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of MCHC(g/dL)
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Albumin analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of albumin(g/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Hematocrit analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of Hematocrit(%).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
RDW-CV analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of RDW-CV(%).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
HbA1C analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of HbA1C(%).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
MCV analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of MCV(fL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
MCH analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of MCH(pg).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Platelets analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of Platelets(k/uL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
WBC analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of WBC(k/uL) .
|
Change from baseline outcome measure at 10th week (post-test)
|
|
AST analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of AST(U/L).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
ALT analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of ALT(U/L).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
GGT analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of GGT(U/L).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
T-Cholesterol analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of T-Cholesterol(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Triglyceride analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of triglyceride(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
BUN analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of BUN(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Uric acid analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of Uric acid(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
HDL-C analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of HDL-C(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
LDL-C analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of LDL-C(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
hs-CRP analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of hs-CRP(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Fasting blood glucose analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of fasting blood glucose(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Creatinine analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of creatinine(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Free T4 analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of 【Free T4(ng/dL)】
|
Change from baseline outcome measure at 10th week (post-test)
|
|
hsTSH analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of 【hsTSH(ulU/dL)】
|
Change from baseline outcome measure at 10th week (post-test)
|
|
HOMA-IR analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of 【 HOMA-IR】
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Insulin analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of 【 insulin(uU/dL)】
|
Change from baseline outcome measure at 10th week (post-test)
|
|
eGFR analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of 【eGFR (mL/min/1.73^2)】
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Ca analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Use the Clinical Chemistry Analyzer to detection of Ca(mmol/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
specific gravity index analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes specific gravity index (USG).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine pH analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes pH.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine total protein analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes Total protein (mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine glucose analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes glucose (-/+).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine Urea Nitrogen analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes Urine Urea Nitrogen(-/+).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine ketones analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes ketones(-/+).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine Creatinine analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes Creatinine(mg/dL).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine bilirubin (dipstick) analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes bilirubin (-/+).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine Albumin analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes Albumin(mg/L).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine Albumin/Creatinine analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes Albumin/Creatinine(mg/g).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine Nitrite (dipstick) analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes Nitrite(-/+).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Urine WBC esterase analysis
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Fasting for 8 hours, collecting 10ml urine.
Routine urine analysis which includes WBC esterase(-/+).
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Superoxide dismutase (SOD) Oxidative stress assessment
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Oxidative stress assessment to assess Superoxide dismutase (SOD) in serum was measured by the ELISA kit.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Glutathione peroxidase (GPx) Oxidative stress assessment
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Oxidative stress assessment to assess Glutathione peroxidase (GPx) in serum was measured by the ELISA kit..
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Catalase Oxidative stress assessment
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Oxidative stress assessment to assess Catalase in serum was measured by the ELISA kit..
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Physical examination-Height
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure participants' height.
The height measurement method is to measure after you take off your shoes and step on the machine.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Physical examination- Body weight
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure participants' body weight.
The body weight measurement method is to measure after you take off your shoes and step on the weight machine.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Physical examination - waist circumference
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure participants' waist circumference.
The waist measurement method is to use a tape measure to measure the waist circumference above the human hips.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Physical examination - arm circumference
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure participants' arm circumference.
The measurement method of the arm circumference is the circumference of the upper arm and is measured at the mid-point between the tips of the shoulder and elbow. .
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Physical examination - calf circumference
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure participants' calf circumference.
The measurement method of the calf circumference should be the same as the shoulder width and place the tape measure at the thickest part of the calf with a horizontal line around it for measurement.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Physical examination - hip circumference
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Measure participants' hip circumference.
The hip measurement method is to use a tape measure to measure the maximum hip diameter.
|
Change from baseline outcome measure at 10th week (post-test)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Physical Activity Questionnaire assessment
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Using Physical Activity Questionnaire to assess participants' activity level.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
24-hour Dietary Recall Form
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
The 24-hour diet recall method is conducted by interviewers who have received professional training in food serving size.
Ask participants to recall all food and beverages actually consumed in the past 24 hours and record them in the questionnaire.
Location, and the name, material, quantity and preparation method of food; among them, the estimation of the quantity can be assisted by using food weighing tools and food quantitative aids.
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Gastrointestinal Function Assessment
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
Assess the number of bowel movements, bowel habits, bowel pattern, and flatulence
|
Change from baseline outcome measure at 10th week (post-test)
|
|
Mini nutrition assessment
Aikaikkuna: Change from baseline outcome measure at 10th week (post-test)
|
This Mini nutrition assessment is a Indicator of nutrition status .The score range from 0-30,24 to 30 points represent Normal nutritional status, 17 to 23.5 points represent At the risk of malnutrition, less than 17 points represent Malnourished.
|
Change from baseline outcome measure at 10th week (post-test)
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Opintojen puheenjohtaja: Hui-Yu Huang, Ph.D, Taipei Medical University Graduate Institute of Metabolism and Obesity Sciences
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Perjantai 12. lokakuuta 2018
Ensisijainen valmistuminen (Todellinen)
Tiistai 30. kesäkuuta 2020
Opintojen valmistuminen (Todellinen)
Tiistai 30. kesäkuuta 2020
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Maanantai 15. huhtikuuta 2019
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Sunnuntai 27. kesäkuuta 2021
Ensimmäinen Lähetetty (Todellinen)
Keskiviikko 7. heinäkuuta 2021
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 7. heinäkuuta 2021
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Sunnuntai 27. kesäkuuta 2021
Viimeksi vahvistettu
Tiistai 1. kesäkuuta 2021
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 201806058RINA
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .